Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA: FDA Sees High Fee Collection Rate After First Six Months

Executive Summary

About 24% of facility fees and 20% of all fees are outstanding, but industry officials also want to measure success through FDA hiring and communication.

Advertisement

Related Content

FDA Generics Office Gets Third Director In Three Workdays; Uhl Brings Policy, Pharmacology Experience
FDA Generics Director’s Departure Shows Why Chemistry Matters
GDUFA Launch Pains: Facility List Fluctuations, Back-Due Backlog Fees
GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
ANDA User Fees Will Fund Public Relations-focused Studies On Palatability Of Generics
Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel